Victoria Salem

Victoria Salem

Auto-generated profile, based on publicly available information

Victoria Salem

Department of Bioengineering, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Cell Metabolism
Verified
Journal Article
Open access
ASAkila De Silva
Akila De Silva
VSVictoria Salem
Victoria Salem
CLChristopher J. Long
Christopher J. Long
AMAidan Makwana
Aidan Makwana
RNRexford D. Newbould
Rexford D. Newbould
WDWaljit Dhillo
Waljit Dhillo
Obesity is a major public health issue worldwide. Understanding how the brain controls appetite offers promising inroads toward new therapies for obesity. Peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) are coreleased postprandially and reduce appetite and inhibit food intake when administered to humans. However, the effects of GLP-1 and the ways in which PYY and GLP-1 act together to modulate brain activity in humans are unknown. Here, we have used functional MRI to determine these effects in healthy, normal-weight human subjects and compared them to those seen physiologically following a meal. We provide a demonstration that the combined administration of PYY(3-36) and GLP-1(7-36 amide) to fasted human subjects leads to similar reductions in subsequent energy intake and brain activity, as observed physiologically following feeding.

14 March 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
TTTricia M. Tan
Tricia M. Tan
BFBenjamin C.T. Field
Benjamin C.T. Field
KMKatherine A. McCullough
Katherine A. McCullough
RTRachel C. Troke
Rachel C. Troke
ECEdward Chambers
Edward Chambers
SBStephen R. Bloom
Stephen R. Bloom
Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively. Giving dual agonists with glucagon and GLP-1 activity to diabetic, obese mice causes enhanced weight loss and improves glucose tolerance by reduction of food intake and by increase in energy expenditure (EE). We aimed to observe the effect of a combination of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers. In a randomized, double-blinded crossover study, 10 overweight or obese volunteers without diabetes received placebo infusion, GLP-1 alone, glucagon alone, and GLP-1 plus glucagon simultaneously. Resting EE—measured using indirect calorimetry—was not affected by GLP-1 infusion but rose significantly with glucagon alone and to a similar degree with glucagon and GLP-1 together. Glucagon infusion was accompanied by a rise in plasma glucose levels, but addition of GLP-1 to glucagon rapidly reduced this excursion, due to a synergistic insulinotropic effect. The data indicate that drugs with glucagon and GLP-1 agonist activity may represent a useful treatment for type 2 diabetes and obesity. Long-term studies are required to demonstrate that this combination will reduce weight and improve glycemia in patients.

6 July 2011 in Journal of Obesity
Verified
Journal Article
Open access
PDF file
ASAmir H. Sam
Amir H. Sam
VSVictoria Salem
Victoria Salem
MGMohammad A. Ghatei
Mohammad A. Ghatei
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.

14 June 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
VSVictoria Salem
Victoria Salem
LSLuis Delgadillo Silva
Luis Delgadillo Silva
KSKinga Suba
Kinga Suba
EGEleni Georgiadou
Eleni Georgiadou
SGS. Neda Mousavy Gharavy
S. Neda Mousavy Gharavy
GRGuy A. Rutter
Guy A. Rutter

1 November 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CJChanna N Jayasena
Channa N Jayasena
GNGurjinder M. K. Nijher
Gurjinder M. K. Nijher
OCOwais B. Chaudhri
Owais B. Chaudhri
KMKevin Murphy
Kevin Murphy
ARAmita Ranger
Amita Ranger
WDWaljit Dhillo
Waljit Dhillo
Background: Kisspeptin is a critical regulator of normal reproductive function. A single injection of kisspeptin in healthy human volunteers potently stimulates gonadotropin release. However, the effects of kisspeptin on gonadotropin release in women with hypothalamic amenorrhea (HA) and the effects of repeated administration of kisspeptin to humans are unknown. Aim: The aim of this study was to determine the effects of acute and chronic kisspeptin administration on gonadotropin release in women with HA. Methods: We performed a prospective, randomized, double-blinded, parallel design study. Women with HA received twice-daily sc injections of kisspeptin (6.4 nmol/kg) or 0.9% saline (n = 5 per group) for 2 wk. Changes in serum gonadotropin and estradiol levels, LH pulsatility, and ultrasound measurements of reproductive activity were assessed. Results: On the first injection day, potent increases in serum LH and FSH were observed after sc kisspeptin injection in women with HA (mean maximal increment from baseline within 4 h after injection: LH, 24.0 ± 3.5 IU/liter; FSH, 9.1 ± 2.5 IU/liter). These responses were significantly reduced on the 14th injection day (mean maximal increment from baseline within 4 h postinjection: LH, 2.5 ± 2.2 IU/liter, P < 0.05; FSH, 0.5 ± 0.5 IU/liter, P < 0.05). Subjects remained responsive to GnRH after kisspeptin treatment. No significant changes in LH pulsatility or ultrasound measurements of reproductive activity were observed. Conclusion: Acute administration of kisspeptin to women with infertility due to HA potently stimulates gonadotropin release, but chronic administration of kisspeptin results in desensitization to its effects on gonadotropin release. These data have important implications for the development of kisspeptin as a novel therapy for reproductive disorders in humans. Subcutaneous administration of kisspeptin-54 acutely and potently stimulates gonadotrophin release in women with hypothalamic amenorrhoea, but twice-daily administration over a 2-week period leads to desensitisation to its effects.

26 March 2022 in Obesity Reviews
Verified
Journal Article
Open access
VSVictoria Salem
Victoria Salem
NANoara Alhusseini
Noara Alhusseini
HRHabeeb Ibrahim Abdul Razack
Habeeb Ibrahim Abdul Razack
ANAnastasia Naoum
Anastasia Naoum
OSOmar T Sims
Omar T Sims
SASaleh Alqahtani
Saleh Alqahtani
Summary: Saudi Arabia (SA) has a reported obesity prevalence greater than the global average. Here, we systematically review firstly the prevalence and associated factors (59 studies) and secondly the pharmacological, lifestyle, and surgical interventions for obesity (body mass index, >30 kg/m2) in SA (29 studies) between December 2020 and March 2021 in PubMed, Medline, Embase, PsycINFO, and Cochrane. Peer‐reviewed articles in Arabic and English on human adults (aged >18 years) were searched. Among the eight largest studies with sample sizes over 10,000 people, the maximum‐reported obesity prevalence was 35.6%, with notable variations in gender and geographic region. Diet, specifically the move towards Western diet and heavy consumption of sugary beverages, and high levels of inactivity are major contributing factors to obesity. The reported obesity‐risk polymorphisms are not specific. Bariatric surgery is underrepresented, and in general, there is a lack of nationally coordinated studies on weight loss interventions. In particular, the systematic review did not find a body of research on psychological interventions. There is no trial data for the use of GLP‐1 analogs in SA, despite their widespread use. These findings can help policymakers, and practitioners prioritize future research efforts to reduce obesity prevalence in SA.